Arch Biopartners’ Phase II study in cardiac surgery–associated acute kidney injury (CS-AKI) targets enrollment of 240 on-pump patients, randomizing LSALT peptide 10 mg IV twice daily for five days versus placebo. The primary endpoint is incidence of AKI within seven days post-surgery per KDIGO criteria, aligning dosing and design with prior dose-escalation experience.
The immediate development is operational, not efficacy-related: the University Health Network Research Ethics Board cleared St. Michael’s Hospital in Toronto to join the trial via the Clinical Trials Ontario Stream system. St. Michael’s becomes the ninth activated site globally and the fourth within a core Canadian academic network. Toronto General Hospital and the University of Calgary continue enrolling; Royal Columbian Hospital has local ethics clearance and is moving to site initiation. Additional Canadian and U.S. sites are under evaluation to support accrual.
Strategically, the move tightens execution within a high-throughput perioperative ecosystem while leveraging centralized ethics to compress startup timelines. Prevention studies in CS-AKI are logistically unforgiving; enrollment hinges on just-in-time consent ahead of scheduled procedures, infusion readiness across anesthesia and ICU settings, and consistent lab capture to adjudicate KDIGO endpoints. Concentrating within a unified academic network creates shared SOPs across anesthesiology, cardiac surgery, pharmacy, and research coordination, lowering variability that can erode signal in a 240-patient study where effect size is likely modest. Restricting to on-pump procedures reduces heterogeneity in ischemia-reperfusion exposure, a key design choice when the mechanism targets DPEP1-mediated inflammatory injury.
The mechanistic bet is informed but unproven in this setting. Prior clinical work in acute lung inflammation showed reductions across inflammatory biomarkers, including a statistically significant decrease in CXCL10 at a lower daily dose, strengthening the DPEP1 story without providing renal outcomes. Translating that into a perioperative kidney endpoint will require risk enrichment, standardized creatinine sampling windows, and careful management of confounders such as fluid shifts and nephrotoxin exposure. The five-day, twice-daily IV regimen is operationally feasible in the inpatient window typical for cardiac surgery recovery but demands pharmacy and nursing capacity that can bottleneck multi-site rollout.
For sites, this is a perioperative trial that depends on cross-department coordination more than recruitment marketing. Screening needs to be embedded in surgical scheduling, with rapid lab turnaround and consistent KDIGO staging to avoid endpoint misclassification. CROs and vendors supporting the study should expect heavier operational emphasis on real-time eligibility checks, infusion logistics, and perioperative eSource capture rather than decentralized workflows. Regulators will recognize the unmet need—CS-AKI affects up to 30% of on-pump patients and lacks approved prophylaxis—but will scrutinize durability beyond seven days, staging distribution, dialysis incidence, length of stay, and safety in a hemodynamically dynamic population.
The near-term watchlist centers on enrollment velocity as the ninth site comes online, the timing and composition of U.S. site activations, and whether the sponsor discloses an interim monitoring plan or risk-enrichment tweaks as operations mature. The 240-patient sample leaves little margin for high screen failure or inter-site variability; consistent on-pump case mix and creatinine measurement discipline will be determinative. If the design can deliver a clean KDIGO signal, the program advances with a clearer line of sight to regulatory dialogue in a category without incumbents. If enrollment drags or the effect size dilutes, the sponsor may need to expand sites, tighten inclusion criteria, or extend dosing to maintain power.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
